Connecticut Attorney General's Statement On Tentative $425 Million Cephalon Settlement

November 9, 2007 -- "This agreement in principal - the result of an unprecedented investigative partnership between Connecticut and the U.S. Attorney's Office in Philadelphia - will return millions of dollars to the Medicaid program. If it becomes final, the Cephalon settlement by no means ends Connecticut's intensive ongoing investigation into the company's off-label marketing.

"The proposed settlement - disclosed by Cephalon to shareholders yesterday - involves restitution only for government healthcare programs. My office's significant concerns go vastly beyond those issues. Our investigation has revealed the horrendous consequences of off-label marketing - patients potentially harmed by the company's reckless conduct in promoting its drugs for unapproved uses.

Article continues below...

"Cephalon's irresponsible off-label marketing caused severe harms well beyond wasted taxpayer monies. Our investigation has revealed that the company's careless conduct has inflicted highly significant patient injury. Any resolution of Connecticut's claims must include consumer relief, which we will relentlessly pursue."

Source: Connecticut Attorney General